Molecular‐targeted therapy in advanced renal cell carcinoma based on pharmacokinetics, pharmacodynamics and pharmacogenetics: A proposed strategy
- 1 October 2018
- journal article
- review article
- Published by Wiley in International Journal of Urology
- Vol. 26 (1), 48-56
- https://doi.org/10.1111/iju.13805
Abstract
In advanced renal cell carcinoma, a transition of drug therapies from cytokines to molecular-targeted drugs and immune-oncology drugs provides more clinical benefits to patients, while adequate management is required for various and sometimes serious adverse events. At present, the relationship between the pharmacokinetics of many drugs and their effectiveness or adverse events has been elucidated, and therapeutic drug monitoring is being applied to some immunosuppressive, anti-epileptic and antibacterial drugs in daily clinical practice. Most of the molecular-targeted drugs used in patients with renal cell carcinoma are orally active, and are affected by absorption and disposition, which can be different for each individual. The monitoring of the circulating drug concentration could be beneficial to patients by providing information for the adjustment of drug dose and the maintenance of a therapeutic plasma concentration range. Genetic polymorphisms are known to be involved in pharmacokinetics, and cause individual differences in clinical efficacy and adverse events. Therefore, a more scientific strategy should be used in regard to the treatment of patients with advanced renal cell carcinoma treated with molecular-targeted drugs by accumulating evidence on pharmacodynamics and pharmacogenetics.Keywords
This publication has 69 references indexed in Scilit:
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary StudyPLOS ONE, 2012
- Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 TrialJapanese Journal of Clinical Oncology, 2012
- Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issuesEuropean Journal Of Cancer, 2011
- Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1Japanese Journal of Clinical Oncology, 2010
- Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGETEuropean Journal Of Cancer, 2010
- Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphismBritish Journal of Cancer, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2010
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008